SCIENTIFIC PROGRAMME
SESSION I
THE GENOMIC AND
EPIGENOMIC LANDSCAPE
OF CLL AND CLINICAL
CONSEQUENCES
SESSION II
THE ROLE OF BCR
ACTIVATION AND
SIGNALLING FOR CLL
SESSION III
THERAPEUTIC OPTIONS
FOR CLL
SESSION IV
LONG TERM FOLLOW
UP OF CLINICAL TRIALS
VERSUS REAL WORLD
DATA (OUTSIDE CLINICAL
TRIALS DATA-OCT)
SESSION V
THE INCREASING ROLE
OF THE LEUKAEMIC
MICROENVIRONMENT
SESSION VI
THERAPEUTIC OPTIONS 2 :
THE USE OF CELLULAR
AND NON-CELLULAR
IMMUNOTHERAPIES IN
CLL
SESSION VII
EFFICACY THROUGH
SAFETY
SESSION VIII
CLONAL HETEROGENEITY,
CLONAL EVOLUTION AND
MECHANISMS OF DRUG
RESISTANCE
SESSION IX
CONTRASTING
THERAPEUTIC CONCEPTS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES
2
17:35-18:35 Clinical Poster Walk
Leaders: Matthew Davids (Boston), Alessandra Tedeschi (Milan)
18:35-20:30 Dinner break. BUT do not forget to come back for….
SESSION III – Therapeutic options for CLL
Chairs: Alain Delmer (Reims), Michael Hallek (Cologne)
20:30-20:35 Introduction Alain Delmer (Reims)
Michael Hallek (Cologne)
20:35-20:50 Ibrutinib for everybody Jennifer Woyach (Columbus)
20:50-21:05 Ibrutinib for a small subgroup only Florence Cymbalista (Bobigny)
21:05-21:20 MURANO and MRD John Seymour (Melbourne)
21:20-21:35 CLL14 update Kirsten Fischer (Cologne)
SHORT ORAL COMMUNICATION
21:35-21:42 Neddylation pathway regulates treg differentiation
and T-cell function in Chronic Lymphocytic Leukemia
ex vivo and murine in vivo studies Scott Best (Portland)
21:42-22:12 General Discussion
Tuesday, November 17, 2020
13:00-14:00 Simultaneous Lunchtime Meet the Expert sessions
1. Prognostic and predictive markers Barbara Eichhorst (Cologne)/Loic Ysebaert (Toulouse)
2. First line therapy: continuous or time limited treatment? Michael Hallek (Cologne)/Alessandra Tedeschi (Milan)
SESSION IV – Long term follow up of clinical trials versus real world data (Outside Clinical Trials data-OCT)
Chair: Jennifer Woyach (Columbus)
14:05-14:10 Introduction Jennifer Woyach (Columbus)
14:10-14:25 Ibrutinib trials Alessandra Tedeschi (Milan)
14:25-14:40 Ibrutinib real world Loïc Ysebaert (Toulouse)
14:40-14:55 Venetoclax trials Matthew Davids (Boston)
14:55-15:10 Venetoclax / PI3K real world Lindsey Roeker (New York)
SHORT ORAL COMMUNICATION
15:10-15:17 Sequential treatment with bendamustine, obinutuzumab
(GA101) and ibrutinib in Chronic Lymphocytic Leukemia:
final results of the CLL2-BIG trial of the German
CLL study group (GCLLSG) Julia von Tresckow (Essen)
15:17-15:45 General discussion